Epigenetic regulatory enzymes are generally considered innovative targets for cancer therapy and several histone methyltransferase inhibitors are currently being evaluated in phase I and phase II clinical trials. In this commentary, we discuss the need for better functional understanding of histone methyltransferases and especially of their potential non-histone substrates. Rodríguez-Paredes and Lyko argue that non-histone proteins should be considered when assessing cancer drugs that target protein methylation.

中文翻译：

---

非组蛋白蛋白质甲基化在癌症治疗中的重要性。

表观遗传调节酶通常被认为是癌症治疗的创新目标，目前正在I期和II期临床试验中评估几种组蛋白甲基转移酶抑制剂。在这篇评论中，我们讨论了对组蛋白甲基转移酶，尤其是其潜在的非组蛋白底物更好的功能理解的需求。Rodríguez-Paredes和Lyko认为，在评估靶向蛋白质甲基化的抗癌药物时，应考虑使用非组蛋白蛋白质。